Skip to content
Facebook page opens in new windowInstagram page opens in new windowYouTube page opens in new window
Search:
DONATE
ALD Connect
ALD ConnectALD Connect
  • About Us
    • Mission
    • Board of Directors
    • The Myelin Project
    • Our Partners
  • What is ALD?
    • ALD Centers and Experts
    • Newborn Screening/Asymptomatic
    • Adrenal Insufficiency
    • Cerebral ALD
    • Adrenomyeloneuropathy (AMN)
    • Symptomatic Women
  • Clinical Trials & Research
    • Clinical Trials
    • Laboratories
    • Publications
  • EL-PFDD
  • Resources
    • Annual Meetings
    • Financial Assistance
    • Frequently Asked Questions
    • Patient Learning Academies
    • Peer Mentor Program
    • Webinars
  • Get Involved
    • Advocate
    • ALD Landscape Project
    • Community Calendar
    • Community Calls
    • Community Directory
  • News
  • Contact Us
  • About Us
    • Mission
    • Board of Directors
    • The Myelin Project
    • Our Partners
  • What is ALD?
    • ALD Centers and Experts
    • Newborn Screening/Asymptomatic
    • Adrenal Insufficiency
    • Cerebral ALD
    • Adrenomyeloneuropathy (AMN)
    • Symptomatic Women
  • Clinical Trials & Research
    • Clinical Trials
    • Laboratories
    • Publications
  • EL-PFDD
  • Resources
    • Annual Meetings
    • Financial Assistance
    • Frequently Asked Questions
    • Patient Learning Academies
    • Peer Mentor Program
    • Webinars
  • Get Involved
    • Advocate
    • ALD Landscape Project
    • Community Calendar
    • Community Calls
    • Community Directory
  • News
  • Contact Us

Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy

UncategorizedBy KellyJanuary 8, 2021

Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy

© ALD Connect | Website Design & Website Development by Surf Your Name.
Go to Top